View printer-friendly version |
Charles River Laboratories and The Tri-Institutional Therapeutics Discovery Institute Announce Strategic Partnership
Partnership Intends to Accelerate Translation of Discoveries into Novel Therapies for Patients
Tri-I TDI is a cooperative endeavor of
“This partnership reinforces Charles River’s continued commitment to
expedite the early-stage development of innovative treatments and
therapies for patients,” said Dr.
Through this partnership, Charles River will provide Tri-I TDI with discovery and safety assessment services to support a range of projects that are at the frontier of science. The collaboration will enhance Tri-I TDI’s efforts to more effectively develop therapeutics for unmet medical needs.
“Our partnership with Charles River opens up a new pathway to innovation
for Tri-I TDI,” said
About
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160922005165/en/
Source:
Charles River Laboratories International, Inc.
Investor Contact:
Susan
E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media
Contact:
Amy Cianciaruso, 781-222-6168
Corporate Vice
President, Public Relations
amy.cianciaruso@crl.com